Brought to you by 
Cannasat negotiates deal for Adagio's Parkinson's candidate; terminated
17 Jun 2022
Executive Summary
Spec CNS pharma Cannasat Therapeutics and recently formed Adagio Pharmaceuticals are negotiating an exclusive global development and commercialization license for the latter's APL130277 for Parkinson's disease. If the agreement is finalized, Cannasat will have 12 months to make a decision, and plans to conduct due diligence and proof-of-concept studies.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cannasat negotiates deal for Adagio's Parkinson's candidate; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice